Aug 9 : Nearly three years after first winning accelerated FDA approval of Gavreto (pralsetinib) in metastatic non-small cell lung cancer (NSCLC) with RET fusions, Genentech (Roche) and Blueprint Medicines announced the drugs conversion to full approval
Now to be sold under the brand name Sohonos, the oral medication is indicated for the reduction of heterotrophic ossification in adults and children with FOP
Key proposed mechanisms include: Angiogenesis
If your body has a vitamin B12 deficiency, this can affect the replication of DNA, which may increase the risk of cancer, heart attack, or stroke
Ishaq HM, Mohammad IS, Guo H, Shahzad M, Hou YJ, Ma C et al (2017) Molecular estimation of alteration in intestinal microbial composition in Hashimotos thyroiditis patients
Our team is always available to provide additional support if you need more personalised guidance, ensuring that you feel informed and confident every step of the way